

CERTIFICATE OF AMENDMENT TO
RESTATED CERTIFICATE OF INCORPORATION
OF
CONCERT PHARMACEUTICALS, INC.

(Pursuant to Section 242 of the
Delaware General Corporation Law)

Concert Pharmaceuticals, Inc. (the "Corporation"), a corporation organized and existing under and by virtue of the provisions of the Delaware General Corporation Law (the "DGCL"), does hereby certify as follows:

A resolution was duly adopted by the Board of Directors of the Corporation pursuant to Section 242 of the DGCL setting forth a proposed amendment to the Restated Certificate of Incorporation of the Corporation and declaring said amendment to be advisable. The stockholders of the Corporation duly approved said proposed amendment in accordance with Section 242 of the DGCL. The resolution setting forth the amendment is as follows:

RESOLVED: That the first paragraph of Article FOURTH of the Restated Certificate of Incorporation of the Corporation be and hereby is deleted in its entirety and the following is inserted in lieu thereof:

"FOURTH: The total number of shares of all classes of stock which the Corporation shall have authority to issue is 205,000,000 shares, consisting of (i) 200,000,000 shares of Common Stock, par value \$0.001 per share ("Common Stock"), and (ii) 5,000,000 shares of Preferred Stock, par value \$0.001 per share ("Preferred Stock")."

IN WITNESS WHEREOF, this Certificate of Amendment has been executed by its duly authorized officer this 9th day of June, 2022.

CONCERT PHARMACEUTICALS, INC.

By: /s/ Roger D. Tung
Name: Roger D. Tung
Title: President and Chief Executive Officer